Review of common sexually transmitted diseases; Focus on ustekinumab; Drug Watch: Agents in late-stage development for the treatment of pulmonary diseases
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More